FDA, EU To Redouble Inspection Of Asian Pharmaceutical Supply Chains
Mutual recognition agreement enables US and European authorities to redirect inspectional resources to China and India. The result could be more warning letters and other actions unless global companies strengthen oversight of ingredient suppliers and contract manufacturers in Asia, current and former FDA officials say.
You may also be interested in...
Leveraging foreign surveillance inspections could help FDA ensure more sites are inspected more often.
Dara Corrigan will become Fresenius-Kabi’s VP for global affairs and policy.
US FDA warning letters to Chinese firms may be on the increase, but ties with the Chinese regulator appear to be growing. US FDA showcases how to get more done in fast-changing China via aligning with China FDA's aspiration for quality and international harmonization.